Search Results - "heterologous"

Implantation of a heterologous dermo-epidermal skin substitute in a patient with deep dermal burn that enhances biomechanical and functional recovery: Case report by M.C. Ornelas-Flores, J. García-López, Y. Melgarejo-Ramírez, R. Sánchez-Sánchez, G. Leyva-Gómez, N. Zacaula-Juárez, O. González-Mendoza, H.A. Manzo-Castrejón, F.E. Ferreira-Aparicio, E. Márquez-Gutiérrez, M.E. Martínez-Pardo, M.C. Velasquillo-Martínez, J.C. Ibarra-Ponce de León, A.M. Brena-Molina

Connect to this object online.

Low-grade endometrial stromal sarcoma with extensive sex cord differentiation, heterologous elements, and complex atypical hyperplasia: Case report and review of literature by Abby M. Richmond, Andrew J. Rohrer, Susan A. Davidson, Miriam D. Post

Connect to this object online.

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review by Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu

Connect to this object online.

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine by Xiaolan Yong, Jun Liu, Ying Zeng, Jing Nie, Xuelian Cui, Tao Wang, Yilin Wang, Yiyong Chen, Wei Kang, Zhonghua Yang, Yan Liu

Connect to this object online.

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines by Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda

Connect to this object online.

Maxillary Sinus Augmentation with Xenogenic Collagen-Retained Heterologous Cortico-Cancellous Bone: A 3-Year Follow-Up Randomized Controlled Trial by Francisco Correia, Sónia Gouveia, António Campos Felino, Ricardo Faria-Almeida, Daniel H. Pozza

Connect to this object online.

The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees by Francesca Dapporto, Margherita Leonardi, Claudia Maria Trombetta, Claudia Semplici, Pietro Piu, Giulia Piccini, Linda Benincasa, Serena Marchi, Emanuele Andreano, Piero Lovreglio, Nicola Buonvino, Nicola Decaro, Angela Stufano, Eleonora Lorusso, Emilio Bombardieri, Antonella Ruello, Simonetta Viviani, Rino Rappuoli, Eleonora Molesti, Alessandro Manenti, Emanuele Montomoli

Connect to this object online.

Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation by Yingze Zhao, Xin Zhao, Rong Zhang, Beiwei Ye, Xiaoju Yuan, Danni Zhang, Lei Li, Jinmin Tian, Yaxin Guo, George F. Gao, William J. Liu

Connect to this object online.

A Heterologous Multiepitope DNA Prime/Recombinant Protein Boost Immunisation Strategy for the Development of an Antiserum against Micrurus corallinus (Coral Snake) Venom. by Henrique Roman Ramos, Inácio de Loiola M Junqueira-, Juliana Branco Novo, Karen Castro, Clara Guerra Duarte, Ricardo A Machado-, Carlos Chavez-Olortegui, Paulo Lee Ho

Connect to this object online.

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines by Anthony M. Marchese, Raj Kalkeri, Muruga Vadivale, Nungruthai Suntronwong, Seth Toback, Yong Poovorawan

Connect to this object online.

Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant by Gabiria Pastore, Jacopo Polvere, Fabio Fiorino, Simone Lucchesi, Giorgio Montesi, Ilaria Rancan, Sara Zirpoli, Arianna Lippi, Miriam Durante, Massimiliano Fabbiani, Mario Tumbarello, Francesca Montagnani, Donata Medaglini, Annalisa Ciabattini

Connect to this object online.

Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine by Qian Chen, Pei Du, Yuxuan Han, Xuehui Ma, Rong Zhang, Xiaoyu Rong, Xu Zhao, Renyi Ma, Huiting Yang, Anqi Zheng, Qingrui Huang, Jinghua Yan, Hui Wang, Xin Zhao, Lianpan Dai, George F. Gao, Qihui Wang

Connect to this object online.

<span style="font-variant: small-caps">l</span>-Asparaginase Type II from <i>Fusarium proliferatum</i>: Heterologous Expression and In Silico Analysis by Samuel Leite Cardoso, Paula Monteiro Souza, Kelly Rodrigues, Isabella de Souza Mota, Edivaldo Ferreira Filho, Léia Cecilia de Lima Fávaro, Felipe Saldanha-Araujo, Mauricio Homem-, Adalberto Pessoa, Dâmaris Silveira, Yris Maria Fonseca-Bazzo, Pérola Oliveira Magalhães

Connect to this object online.

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines by Camilo C. Roa, Mari Rose A. de Los Reyes, Eric Plennevaux, Igor Smolenov, Branda Hu, Faith Gao, Hannalyn Ilagan, Donna Ambrosino, George Siber, Ralf Clemens, Htay Htay Han

Connect to this object online.

Expression of heterologous oxalate decarboxylase in HEK293 cells confers protection against oxalate induced oxidative stress as a therapeutic approach for calcium oxalate stone disease by Abhishek Albert, Vidhi Tiwari, Eldho Paul, Divya Ganesan, Mahesh Ayyavu, Ritu Kujur, Sasikumar Ponnusamy, Kathiresan Shanmugam, Luciano Saso, Selvam Govindan Sadasivam

Connect to this object online.

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks by Georgi Shukarev, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, the EBOVAC1 consortium

Connect to this object online.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). by Asha Jayakumar, Tiago M Castilho, Esther Park, Karen Goldsmith-Pestana, Jenefer M Blackwell, Diane McMahon-Pratt

Connect to this object online.

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia by I. V. Dolzhikova, O. V. Zubkova, A. I. Tukhvatulin, A. S. Dzharullaeva, N. M. Tukhvatulina, D. V. Shcheblyakov, M. M. Shmarov, E. A. Tokarskaya, Y. V. Simakova, D. A. Egorova, D. N. Scherbinin, I. L. Tutykhina, A. A. Lysenko, A. V. Kostarnoy, P. G. Gancheva, T. A. Ozharovskaya, B. V. Belugin, L. V. Kolobukhina, V. B. Pantyukhov, S. I. Syromyatnikova, I. V. Shatokhina, T. V. Sizikova, I. G. Rumyantseva, A. F. Andrus, N. V. Boyarskaya, A. N. Voytyuk, V. F. Babira, S. V. Volchikhina, D. A. Kutaev, A. N. Bel'skih, K. V. Zhdanov, S. M. Zakharenko, S. V. Borisevich, D. Y. Logunov, B. S. Naroditsky, A. L. Gintsburg

Connect to this object online.

Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a by Qing Liu, Huali Su, Xiaoping Bian, Shifeng Wang, Qingke Kong

Connect to this object online.

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination by Jaeeun Yoo, Younjeong Kim, Yu mi Cha, Jaewoong Lee, Yeon Jeong Jeong, Si-Hyun Kim, Lisa L. Maragakis, Seungok Lee

Connect to this object online.